Vadadustat Post-hoc Analysis Published in JASN Shows Significant Mortality & Hospitalization Reduction
AKBA sits 25% above its 52-week low of $1.14.
Summary
Akebia Therapeutics announced the publication of a post-hoc analysis from its Phase 3 INNO2VATE program in the Journal of the American Society of Nephrology (JASN). The analysis revealed a statistically significant reduction in a hierarchical composite endpoint of all-cause mortality and hospitalization for vadadustat (Vafseo) compared to darbepoetin alfa in dialysis-dependent chronic kidney disease patients. This publication provides crucial clinical validation and differentiation for Vafseo, an already approved and launched product that has been available in the U.S. since January 2025 and is contributing to the company's revenue. The strong clinical claim of reduced mortality and hospitalization can significantly enhance physician confidence and prescribing behavior, potentially accelerating market adoption and sales growth. Traders should monitor Vafseo's sales performance and any future updates on its market penetration.
At the time of this announcement, AKBA was trading at $1.42 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $375.6M. The 52-week trading range was $1.14 to $4.08. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.